Drugs / RO5045337
Trials 6
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT01677780 | Nov 2012 → Jun 2017 | myeloid leukemia | Hoffmann-La Roche | Completed | No outcome recorded |
| Phase 1 | NCT01605526 | May 2012 → Jun 2013 | sarcoma | Hoffmann-La Roche | Completed | No outcome recorded |
| Phase 1 | NCT01164033 | Aug 2010 → May 2013 | neoplasm | Hoffmann-La Roche | Completed | No outcome recorded |
| Phase 1 | NCT01143740 | Jun 2010 → Mar 2011 | sarcoma | Hoffmann-La Roche | Completed | No outcome recorded |
| Phase 1 | NCT00623870 | May 2008 → Nov 2012 | hematopoietic and lymphoid cell neoplasm | Hoffmann-La Roche | Completed | No outcome recorded |
| Phase 1 | NCT00559533 | Dec 2007 → Nov 2012 | neoplasm | Hoffmann-La Roche | Completed | No outcome recorded |
Evidence & citations 9 cited values
Every value below carries the sentence it was read from. 7 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | RO5045337 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01143740 ↗ |
| Known as | MDM2 ANTAGONIST RO5045337 | ChEMBL registry synonym — accepted as the source's own label CHEMBL2386346 ↗ |
| Known as | R 7112 | ChEMBL registry synonym — accepted as the source's own label CHEMBL2386346 ↗ |
| Known as | RG7112 | “A Study of RO5045337 [RG7112] in Patients With Hematologic Neoplasms.” NCT00623870 ↗1“A Study of RO5045337 [RG7112] in Patients With Advanced Solid Tumors” NCT00559533 ↗ |
| Known as | UNII-Q8MI0X869M | ChEMBL registry synonym — accepted as the source's own label CHEMBL2386346 ↗ |
| Action | Inhibit | “RO5045337, an Oral Small Molecule MDM2 Antagonist” NCT01605526 ↗ |
| Modality | Small molecule | “RO5045337, an Oral Small Molecule MDM2 Antagonist” NCT01605526 ↗ |
| Route | Oral | “Administered po at escalating doses” NCT00559533 ↗ |
| Target | MDM2 | “RO5045337, an Oral Small Molecule MDM2 Antagonist” NCT01605526 ↗ |